Steeve Provencher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1214236/publications.pdf

Version: 2024-02-01

94	7,067	66234	58464
papers	citations	42 h-index	82 g-index

95	95	95	6047
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040
2	Role for miR-204 in human pulmonary arterial hypertension. Journal of Experimental Medicine, 2011, 208, 535-548.	4.2	487
3	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	0.6	277
4	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	1.0	272
5	Role for DNA Damage Signaling in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 786-797.	1.6	211
6	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	1.2	209
7	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
8	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 291-305.	5.2	190
9	Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation, 2015, 132, 932-943.	1.6	173
10	Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans. Cell Metabolism, 2014, 20, 827-839.	7.2	170
11	Signal Transducers and Activators of Transcription-3/Pim1 Axis Plays a Critical Role in the Pathogenesis of Human Pulmonary Arterial Hypertension. Circulation, 2011, 123, 1205-1215.	1.6	156
12	The cancer theory of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 285-299.	0.8	154
13	Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax, 2010, 65, 113-117.	2.7	150
14	Bromodomain-Containing Protein 4. Circulation Research, 2015, 117, 525-535.	2.0	143
15	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
16	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 515-529.	2.5	134
17	Novel insights on the pulmonary vascular consequences of COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L277-L288.	1.3	125
18	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	2.5	113

#	Article	IF	Citations
19	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research, 2018, 122, 1021-1032.	2.0	111
20	Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. European Respiratory Journal, 2006, 27, 114-120.	3.1	108
21	miR-223 reverses experimental pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2015, 309, C363-C372.	2.1	103
22	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768.	0.4	102
23	A miR-208â€“Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension. Circulation Research, 2015, 116, 56-69.	2.0	101
24	Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 910-920.	2.5	100
25	Impaired Angiogenesis and Peripheral Muscle Microcirculation Loss Contribute to Exercise Intolerance in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 318-328.	2.5	99
26	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation, 2020, 142, 1464-1484.	1.6	96
27	Effects of a Rehabilitation Program on Skeletal Muscle Function in Idiopathic Pulmonary Arterial Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2010, 30, 319-323.	1.2	92
28	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285.	2.5	88
29	DNA Damage and Pulmonary Hypertension. International Journal of Molecular Sciences, 2016, 17, 990.	1.8	85
30	Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. European Respiratory Journal, 2008, 32, 393-398.	3.1	84
31	Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension. Circulation Research, 2020, 126, 1723-1745.	2.0	83
32	Assessment of Daily Life Physical Activities in Pulmonary Arterial Hypertension. PLoS ONE, 2011, 6, e27993.	1.1	76
33	Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 90-103.	2.5	75
34	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1513-1523.	1.1	72
35	HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension. Scientific Reports, 2017, 7, 4546.	1.6	70
36	Signal Transduction in the Development of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 278-293.	0.8	69

#	Article	IF	Citations
37	Potassium channels in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 1167-1177.	3.1	64
38	FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. Journal of Molecular Medicine, 2018, 96, 223-235.	1.7	62
39	Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. Journal of Molecular Medicine, 2015, 93, 573-584.	1.7	53
40	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 148-157.	2.5	53
41	Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 244-260.	2.5	52
42	17Î²-estradiol and estrogen receptor Î± protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. Journal of Clinical Investigation, 2021, 131, .	3.9	47
43	Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest, 2014, 146, 686-708.	0.4	43
44	Impaired Skeletal Muscle Oxygenation and Exercise Tolerance in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2015, 47, 2273-2282.	0.2	43
45	Inhibition of CHK 1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1667-1681.	1.1	40
46	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
47	Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vascular Pharmacology, 2021, 139, 106882.	1.0	33
48	Compromised Cerebrovascular Regulation and Cerebral Oxygenation in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	32
49	Extended Anticoagulation for VTE. Chest, 2019, 155, 1199-1216.	0.4	26
50	Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. American Journal of Physiology - Cell Physiology, 2020, 318, C1-C28.	2.1	26
51	miRNAs in PAH: biomarker, therapeutic target or both?. Drug Discovery Today, 2014, 19, 1264-1269.	3.2	25
52	Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS ONE, 2019, 14, e0214134.	1.1	25
53	Current Treatment Approaches to Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2015, 31, 460-477.	0.8	24
54	Anti-inflammatory and Immunosuppressive Agents in PAH. Handbook of Experimental Pharmacology, 2013, , 437-476.	0.9	24

#	Article	IF	Citations
55	DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 661-667.	1.0	23
56	Anti-inflammatory and Immunosuppressive Agents in PAH. Handbook of Experimental Pharmacology, 2013, 218, 437-476.	0.9	23
57	Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 614-627.	2.5	22
58	Dual ET_A/ET_B blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-15.	0.8	19
59	Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Thrombosis Research, 2021, 197, 24-32.	0.8	17
60	PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 783-801.	1.1	16
61	Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. European Respiratory Review, 2021, 30, 200284.	3.0	16
62	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. Science Advances, 2021, 7, eabh3794.	4.7	16
63	Alternatives to the Six-Minute Walk Test in Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e103626.	1.1	15
64	Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis. Pharmacological Research, 2021, 163, 105317.	3.1	15
65	BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1357-1360.	2.5	15
66	The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. Expert Review of Respiratory Medicine, 2013, 7, 43-55.	1.0	14
67	Pulmonary Disease, Pulmonary Hypertension and Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 141-153.	0.7	14
68	PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension. JACC Basic To Translational Science, 2022, 7, 384-403.	1.9	14
69	Diagnostic yield of nonâ€guided flexible bronchoscopy for peripheral pulmonary neoplasia. Thoracic Cancer, 2015, 6, 517-523.	0.8	13
70	Therapeutic Value of ASK1 Inhibition in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 284-286.	2.5	13
71	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0204610.	1.1	13
72	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 177-198.	0.2	13

#	Article	IF	Citations
73	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274.	0.4	12
74	Implication of EZH2 in the Pro-Proliferative and Apoptosis-Resistant Phenotype of Pulmonary Artery Smooth Muscle Cells in PAH: A Transcriptomic and Proteomic Approach. International Journal of Molecular Sciences, 2021, 22, 2957.	1.8	9
75	Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 2919.	1.8	9
76	Fetal Gene Reactivation in Pulmonary Arterial Hypertension: GOOD, BAD, or BOTH?. Cells, 2021, 10, 1473.	1.8	9
77	Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0120657.	1.1	9
78	Early Evidence for the Role of lncRNA TUG1 in Vascular Remodelling in Pulmonary Hypertension. Canadian Journal of Cardiology, 2019, 35, 1433-1434.	0.8	7
79	Continuous reduction in cerebral oxygenation during endurance exercise in patients with pulmonary arterial hypertension. Physiological Reports, 2020, 8, e14389.	0.7	7
80	Near-fatal haemoptysis as presentation of a giant intralobar pulmonary sequestration. European Respiratory Review, 2015, 24, 155-156.	3.0	6
81	Outcomes following a negative computed tomography pulmonary angiography according to pulmonary embolism prevalence: a metaâ€analysis of the management outcome studies. Journal of Thrombosis and Haemostasis, 2018, 16, 1107-1120.	1.9	5
82	TAKling GDF-15 and skeletal muscle atrophy in pulmonary hypertension: are we there yet?. Thorax, 2019, 74, 103-105.	2.7	5
83	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension. Chest, 2018, 153, 1142-1152.	0.4	4
84	Management of Severe Pulmonary Hypertensive Disease for Surgical and Nonsurgical Procedures. International Anesthesiology Clinics, 2018, 56, e28-e55.	0.3	4
85	Pulmonary hypertension thresholds: time to lower further?. Lancet Respiratory Medicine,the, 2020, 8, 834-836.	5.2	4
86	Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 180020.	3.0	3
87	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.2	3
88	Clinical trial research in focus: improving drug development and trial design in pulmonary arterial hypertension. Lancet Respiratory Medicine,the, 2017, 5, 544-546.	5.2	2
89	Pulmonary tumor thrombotic microangiopathy: A systematic review of the literature. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 20-27.	0.2	2
90	Role of PKM2-PARP1/Inflammation/Oxidative DNA Damage Axis in the Pathogenesis of Right Ventricular Failure Associated with Pulmonary Arterial Hypertension. , 2020, , .		1

#	Article	IF	Citations
91	Long Non-Coding RNA H19 Promotes Right Ventricular Failure in PAH. , 2020, , .		1
92	Long Non-Coding RNA H19 in the Pathogenesis of Right Ventricular Failure Associated with Pulmonary Arterial Hypertension -A Putative Novel Biomarker and Therapeutic Target-. , 2019, , .		0
93	Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1313-1314.	2.5	0
94	Pulmonary vascular diseases. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S2-S5.	0.2	0